Aclaris Therapeutics (ACRS) Earnings Date, Estimates & Call Transcripts $1.15 +0.07 (+6.48%) Closing price 04/11/2025 04:00 PM EasternExtended Trading$1.17 +0.02 (+1.74%) As of 04/11/2025 06:25 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Earnings Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock Aclaris Therapeutics Earnings Summary Upcoming Q4 Earnings DateMay. 6Before Market OpensEstimatedConsensus EPS (Nov. 6) -$0.08 Actual EPS (Nov. 6) -$0.11 Missed By -$0.03 Actual Revenue (Nov. 6) $4.35MAclaris Therapeutics posted Q3 2024 earnings on November 6, 2024, reporting an EPS of -$0.11, which missed analysts' consensus estimates of -$0.08 by $0.03. Quarterly revenue was reported to be $4.35 million, below analyst estimates of $8.31 million. With a trailing EPS of -$1.51, Aclaris Therapeutics' earnings are expected to grow next year, from ($0.82) to ($0.62) per share. Q3 2024 Earnings ResourcesQ3 2024 Earnings Report Quarterly Report (10-Q) Press Release (8-K)ACRS Upcoming EarningsAclaris Therapeutics' Q1 2025 earnings is scheduled for Tuesday, May 6, 2025, with a conference call scheduled at 5:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Q1 2025 Earnings ReportPowered by Get Aclaris Therapeutics Earnings Alerts Want to stay updated on the latest earnings announcements and upcoming reports? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Aclaris Therapeutics and other key companies, straight to your inbox. Enter your email to sign up for newsletter Sign Up Skip Charts & View Estimated and Actual Earnings DataACRS Earnings Estimates and Actuals by QuarterEarnings Estimates and Acutals by Quarter Chart DescriptionThe chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.ACRS Estimated and Actual Revenue by QuarterEstimated Revenue and Actual Revenue by Quarter Chart DescriptionThe chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter. Remove Ads Aclaris Therapeutics Analyst EPS EstimatesQuarterNumber of EstimatesLow EstimateHigh EstimateAverage EstimateQ1 20253-$0.17-$0.10-$0.13Q2 20253-$0.16-$0.13-$0.15Q3 20253-$0.17-$0.15-$0.16Q4 20253-$0.19-$0.16-$0.18FY 202512($0.69)($0.54)($0.62) Remove Ads Aclaris Therapeutics Earnings History by Quarter Custom Range 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 5 Years 10 Years Time Frame * Start Date * End Date Export to Excel DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueDetails 5/6/2025(Estimated)-------11/6/2024--$0.08-$0.11 -$0.03-$0.11$8.31M$4.35M8/7/2024--$0.19-$0.15+$0.04-$0.15$1.74M$2.77M5/7/2024Q1 2024-$0.28-$0.24+$0.04-$0.24$1.99M$2.40M2/27/2024Q4 2023-$0.37-$0.30+$0.07-$0.58$3.96M$17.57M11/6/2023Q3 2023-$0.48-$0.41+$0.07-$0.41$1.57M$9.30M8/7/2023Q2 2023-$0.45-$0.42+$0.03-$0.42$1.90M$1.90M5/8/2023Q1 2023-$0.44-$0.42+$0.02-$0.42$1.75M$2.50M Aclaris Therapeutics Earnings - Frequently Asked Questions When is Aclaris Therapeutics's earnings date? Aclaris Therapeutics has not confirmed its next earnings publication date, but the company's estimated earnings date is Tuesday, May 6th, 2025 based off last year's report dates. Learn more on ACRS's earnings history. Did Aclaris Therapeutics beat their earnings estimates last quarter? In the previous quarter, Aclaris Therapeutics (NASDAQ:ACRS) missed the analysts' consensus estimate of ($0.08) by $0.03 with a reported earnings per share (EPS) of ($0.11). Learn more on analysts' earnings estimate vs. ACRS's actual earnings. How much revenue does Aclaris Therapeutics generate each year? Aclaris Therapeutics (NASDAQ:ACRS) has a recorded annual revenue of $18.72 million. How much profit does Aclaris Therapeutics generate each year? Aclaris Therapeutics (NASDAQ:ACRS) has a recorded net income of -$88.48 million. ACRS has generated -$1.51 earnings per share over the last four quarters. What is Aclaris Therapeutics's EPS forecast for next year? Aclaris Therapeutics's earnings are expected to grow from ($0.82) per share to ($0.62) per share in the next year. More Earnings Resources from MarketBeat Related Companies KALV Earnings Date AVBP Earnings Date TRVI Earnings Date RCKT Earnings Date PHAR Earnings Date ANAB Earnings Date LENZ Earnings Date COGT Earnings Date BCAX Earnings Date IMNM Earnings Date Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Why Analysts Boosted United Airlines Stock Ahead of EarningsLamb Weston Stock Rises, Earnings Provide Calm Amidst ChaosIntuitive Machines Gains After Earnings Beat, NASA Missions AheadCintas Delivers Earnings Beat, Signals More Growth AheadNike Stock Dips on Earnings: Analysts Weigh in on What’s NextAfter Massive Post Earnings Fall, Does Hope Remain for MongoDB?Semtech Rallies on Earnings Beat—Is There More Upside? Remove Ads This page (NASDAQ:ACRS) was last updated on 4/12/2025 by MarketBeat.com Staff From Our PartnersDeFi Coin on Verge of Breakout!Crypto’s down — but the fundamentals aren’t. Strategic investors are using this dip to scoop up undervalued...Crypto 101 Media | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | SponsoredBITCOINDid you miss out on the 1000%+ gains of Bitcoin over the past 5 years? If so, you don't want to miss this.....Awesomely, LLC | SponsoredThree new patents reveal Elon and Trump’s secret “Project America”Right now for a limited time… You can get Tim Bohen’s top 5 Trump stocks for 2025… For only ONE DOLLAR!...Timothy Sykes | SponsoredWARNING to All American InvestorsForget the headlines about the "trade war." This is where a real military showdown between China and the U....Behind the Markets | SponsoredThe Last Time This Happened, Americans Lost BillionsWall Street leaders just held a secret meeting in Las Vegas. What they discussed mirrors 2006 — and the warnin...Banyan Hill Publishing | SponsoredPlease — Don’t PanicMarkets are in turmoil — but TradeSmith CEO Keith Kaplan says panic isn’t the answer. Instead, he believes thi...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aclaris Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Aclaris Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy ACRS Stock Free ACRS Stock Alerts